黑色素瘤的危险因素分析及治疗的研究进展
Research Progress in Risk Factors Analysis and Treatment of Melanoma
DOI: 10.12677/acm.2024.1461801, PDF,   
作者: 顾敬喜：郯城县皮肤病防治站皮肤科，山东 临沂；邹 慧*：临沂市中心医院皮肤科，山东 临沂
关键词: 黑色素瘤；病因；外科手术；靶向治疗；免疫检查点抑制剂；Melanoma； Pathogeny； Surgery； Targeted Therapy； Immune Checkpoint Inhibitor
摘要: 黑色素瘤是由黑色素细胞无调节的克隆生长而引起的，常见于皮肤，亦见于粘膜、眼脉络膜等部位，早期易发生血道和淋巴道转移，恶性程度高且预后差。该病的病因复杂，被认为是由遗传易感性和环境暴露相互作用的结果。近年来除了外科手术外，靶向治疗、免疫检查点抑制剂迅速成为黑色素瘤的研究热点。
Abstract: Melanoma is caused by unregulated clonal growth of melanocytes, which is common in the skin, mucous membrane, choroid and other parts of the eye. It is prone to hematogenous and lymphatic metastasis in the early stage, with a high degree of malignancy and poor prognosis. The etiology of the disease is complex, which is considered to be the result of the interaction between genetic susceptibility and environmental exposure. In recent years, in addition to surgery, targeted therapy and immune checkpoint inhibitors have rapidly become the research focus of melanoma.
文章引用：顾敬喜, 邹慧. 黑色素瘤的危险因素分析及治疗的研究进展[J]. 临床医学进展, 2024, 14(6): 496-500. https://doi.org/10.12677/acm.2024.1461801

参考文献

[1] Guy, G.P., Machlin, S.R., Ekwueme, D.U. and Yabroff, K.R. (2015) Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002-2006 and 2007-2011. American Journal of Preventive Medicine, 48, 183-187. [Google Scholar] [CrossRef] [PubMed]
[2] 刘杰, 朱丽萍, 杨旭丽, 等. 2014年中国皮肤黑色素瘤发病与死亡分析[J]. 中国肿瘤. 2018, 27(4): 241-245. [Google Scholar] [CrossRef] 
[3] Craig, S., Earnshaw, C.H. and Virós, A. (2018) Ultraviolet Light and Melanoma. The Journal of Pathology, 244, 578-585. [Google Scholar] [CrossRef] [PubMed]
[4] 王一芩, 周佳磊, 白凯文, 等. 黑色素瘤的发病机制和治疗方法研究进展[J] . 药物生物技术, 2019, 26(4): 357-361. [Google Scholar] [CrossRef] 
[5] Sample, A. and He, Y. (2017) Mechanisms and Prevention of UV-Induced Melanoma. Photodermatology, Photoimmunology & Photomedicine, 34, 13-24. [Google Scholar] [CrossRef] [PubMed]
[6] Shah, P. and He, Y. (2015) Molecular Regulation of UV‐Induced DNA Repair. Photochemistry and Photobiology, 91, 254-264. [Google Scholar] [CrossRef] [PubMed]
[7] Burns, D., George, J., Aucoin, D., Bower, J., Burrell, S., Gilbert, R., et al. (2019) The Pathogenesis and Clinical Management of Cutaneous Melanoma: An Evidence-Based Review. Journal of Medical Imaging and Radiation Sciences, 50, 460-469.E1. [Google Scholar] [CrossRef] [PubMed]
[8] Pampena, R., Kyrgidis, A., Lallas, A., Moscarella, E., Argenziano, G. and Longo, C. (2017) A Meta-Analysis of Nevus-Associated Melanoma: Prevalence and Practical Implications. Journal of the American Academy of Dermatology, 77, 938-945.E4. [Google Scholar] [CrossRef] [PubMed]
[9] 郭婷婷, 图荪阿依∙吾麦尔, 胡佳捷, 等. 皮肤黑色素瘤患者的预后及影响因素分析[J]. 癌症进展, 2024, 22(2): 141-145.
[10] Cust, A.Ε., Mishra, K. and Berwick, M. (2018) Melanoma–role of the Environment and Genetics. Photochemical & Photobiological Sciences, 17, 1853-1860. [Google Scholar] [CrossRef] [PubMed]
[11] Li, W., Han, J., Widlund, H.R., Correll, M., Wang, Y.E., Quackenbush, J., et al. (2013) CXCR4 Pathway Associated with Family History of Melanoma. Cancer Causes & Control, 25, 125-132. [Google Scholar] [CrossRef] [PubMed]
[12] Brandt, A., Sundquist, J. and Hemminki, K. (2011) Risk of Incident and Fatal Melanoma in Individuals with a Family History of Incident or Fatal Melanoma or Any Cancer. British Journal of Dermatology, 165, 342-348. [Google Scholar] [CrossRef] [PubMed]
[13] Jones, M.S., Jones, P.C., Stern, S.L., Elashoff, D., Hoon, D.S.B., Thompson, J., et al. (2017) The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Annals of Surgical Oncology, 24, 2089-2094. [Google Scholar] [CrossRef] [PubMed]
[14] Utjés, D., Malmstedt, J., Teras, J., Drzewiecki, K., Gullestad, H.P., Ingvar, C., et al. (2019) 2-cm versus 4-cm Surgical Excision Margins for Primary Cutaneous Melanoma Thicker than 2 Mm: Long-Term Follow-Up of a Multicentre, Randomised Trial. The Lancet, 394, 471-477. [Google Scholar] [CrossRef] [PubMed]
[15] 张鹏晓, 胡念. 黑色素瘤免疫治疗作用机制研究进展[J]. 生物技术进展, 2023, 13(6): 900-906. [Google Scholar] [CrossRef] 
[16] Wohlmuth, C. and Wohlmuth-Wieser, I. (2021) Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. American Journal of Clinical Dermatology, 22, 639-651. [Google Scholar] [CrossRef] [PubMed]
[17] Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., et al. (2017) Dabrafenib Plus Trametinib versus Dabrafenib Monotherapy in Patients with Metastatic BRAF V600e/k-Mutant Melanoma: Long-Term Survival and Safety Analysis of a Phase 3 Study. Annals of Oncology, 28, 1631-1639. [Google Scholar] [CrossRef] [PubMed]
[18] Dummer, R., Ascierto, P.A., Gogas, H.J., Arance, A., Mandala, M., Liszkay, G., et al. (2018) Encorafenib Plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS): A Multicentre, Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 19, 603-615. [Google Scholar] [CrossRef] [PubMed]
[19] 孟燕, 蒋明东, 张献全. 黑色素瘤免疫治疗研究进展[J]. 现代医药卫生, 2020, 36(11): 1677-1680. [Google Scholar] [CrossRef] 
[20] Eggermont, A.M.M., Crittenden, M. and Wargo, J. (2018) Combination Immunotherapy Development in Melanoma. American Society of Clinical Oncology Educational Book, 38, 197-207. [Google Scholar] [CrossRef] [PubMed]
[21] Carr, S., Smith, C. and Wernberg, J. (2020) Epidemiology and Risk Factors of Melanoma. Surgical Clinics of North America, 100, 1-12. [Google Scholar] [CrossRef] [PubMed]

为你推荐